mayaro
viru
mayv
genu
alphaviru
mosquitotransmit
emerg
infecti
diseas
caus
acut
febril
ill
rash
headach
nausea
may
turn
incapacit
persist
arthralgia
victim
sinc
discoveri
trinidad
case
mayv
infect
larg
confin
northern
countri
south
america
recent
mayv
case
report
island
nation
caribbean
sea
accompani
report
evid
new
vector
includ
aed
spp
mosquito
recent
implic
global
spread
zika
chikungunya
virus
compet
mayv
transmiss
true
could
facilit
spread
mayv
beyond
current
rang
despit
statu
emerg
viru
licens
vaccin
prevent
mayv
infect
therapeut
treat
describ
develop
test
novel
dna
vaccin
scmayv
encod
syntheticallydesign
consensu
mayv
envelop
sequenc
vivo
electroporationenhanc
immun
mice
vaccin
induc
potent
humor
respons
includ
neutral
antibodi
well
robust
tcell
respons
multipl
epitop
mayv
envelop
importantli
scmayveinduc
immun
respons
protect
suscept
mice
morbid
mortal
follow
mayv
challeng
mayaro
viru
mayv
mosquitotransmit
viru
caus
fever
headach
chill
nausea
joint
pain
last
month
infect
rise
number
case
due
increas
mosquito
circul
threat
epidem
emphas
import
emerg
viru
licens
vaccin
prevent
mayaro
infect
plo
neglect
tropic
diseas
http
doi
mayaro
viru
mayv
alphaviru
togavirida
famili
origin
identifi
island
trinidad
mayv
infect
result
acut
febril
ill
last
day
symptom
includ
rash
headach
nausea
vomit
diarrhea
similar
chikungunya
viru
chikv
infect
approxim
mayvinfect
individu
develop
pain
recurr
arthralgia
last
month
acut
ill
clear
sinc
discoveri
sporad
case
mayv
infect
report
mostli
tropic
area
south
america
serosurvey
suggest
may
also
circul
central
american
countri
first
case
mayv
infect
outsid
south
america
report
island
haiti
highlight
potenti
expans
mayv
rang
includ
island
nation
caribbean
sea
alphavirus
arthropodborn
virus
arbovirus
transmit
anim
reservoir
host
via
mosquito
vector
primari
vector
mayv
haemagogu
spp
mosquito
primarili
resid
rural
region
case
mayv
infect
individu
enter
forest
environ
due
work
travel
recent
vector
compet
studi
shown
aed
aegypti
mosquito
capac
transmit
mayv
spark
fear
viru
may
spread
beyond
current
endem
region
possibl
worldwid
given
wider
geograph
distribut
aed
aegypti
recent
year
aed
spp
mosquito
respons
caus
worldwid
outbreak
flavivirus
includ
dengu
zika
higher
expect
seropreval
central
america
evid
human
infect
mayv
becom
common
widespread
current
approv
vaccin
therapeut
avail
block
treat
mayv
infect
current
contain
measur
focus
minim
humanmosquito
contact
vector
control
alphavirus
like
mayv
singlestrand
posit
sens
rna
genom
encod
four
nonstructur
protein
structur
polyprotein
capsid
along
envelop
mrna
also
encod
polypeptid
contribut
process
membran
insert
precursor
viral
envelop
glycoprotein
cleav
translat
get
incorpor
matur
virion
occasion
frameshift
translat
lead
product
transfram
tf
polypeptid
consist
polypeptid
addit
amino
acid
c
terminu
tf
appear
involv
effici
viru
bud
glycoprotein
form
heterodim
shortli
translat
heterodim
associ
trimer
virion
assembl
glycoprotein
primarili
involv
viru
attach
host
cell
protein
mediat
fusion
viru
host
cell
surfac
virion
target
antimayv
antibodi
respons
protect
vaccin
target
mayv
would
import
tool
imped
spread
well
reduc
elimin
diseas
caus
infect
date
two
mayv
vaccin
develop
shown
immunogen
mice
model
inactiv
viru
vaccin
liveattenu
viru
vaccin
describ
develop
novel
synthet
dnabas
vaccin
target
mayv
lab
previous
use
platform
develop
potent
vaccin
divers
infecti
agent
includ
ebola
viru
middl
east
respiratori
syndrom
coronaviru
merscov
zika
viru
zikv
dnabas
vaccin
cheaper
design
manufactur
deploy
convent
vaccin
platform
capabl
induc
humor
cellular
respons
virtual
risk
caus
diseas
importantli
dna
vector
nonimmunogen
thu
reduct
potenc
multipl
administr
first
gener
dna
vaccin
exhibit
poor
inconsist
immun
improv
plasmid
antigen
design
combin
addit
electropor
ep
enhanc
vaccin
deliveri
greatli
improv
immunogen
vaccin
recent
phase
clinic
trial
novel
synthet
zikv
vaccin
found
induc
cellular
humor
respons
includ
neutral
antibodi
vast
major
studi
volunt
passiv
transfer
postvaccin
sera
volunt
complet
protect
mice
morbid
mortal
follow
zikv
challeng
phase
ii
clinic
trial
therapeut
dna
vaccin
encod
consensu
sequenc
human
papilloma
viru
hpv
protein
induc
antigenspecif
humor
cellular
respons
volunt
epenhanc
deliveri
respons
could
mediat
viral
clearanc
clinic
regress
cervic
dysplasia
volunt
vaccin
describ
scmayv
encod
synthet
design
consensu
fulllength
mayv
envelop
antigen
sequenc
epenhanc
deliveri
scmayv
immunocompet
mice
induc
high
level
cellular
respons
multipl
mayv
epitop
along
robust
antibodi
respons
could
neutral
mayv
infect
vitro
immun
interferon
receptor
knockout
mice
ifnar
scmayv
protect
mice
morbid
mortal
follow
mayv
challeng
protect
model
primarili
due
vaccineinduc
humor
respons
robust
immunogen
scmayv
vaccin
demonstr
support
need
test
vaccin
viabl
mean
halt
spread
viru
protect
individu
mayv
diseas
human
embryon
kidney
vero
atcc
atcc
manassa
va
usa
cell
cultur
media
dulbecco
modifi
eagl
medium
invitrogen
life
scienc
technolog
san
diego
ca
usa
supplement
heatinactiv
fetal
calf
serum
fc
mm
glutamin
uml
penicillin
uml
streptomycin
mous
splenocyt
cultur
media
invitrogen
life
scienc
technolog
san
diego
ca
usa
supplement
heatinactiv
fc
mm
glutamin
uml
penicillin
uml
streptomycin
cell
type
cultur
incub
set
co
synthet
mayv
vaccin
dna
construct
encod
fulllength
mayv
envelop
sequenc
consensu
gene
insert
comput
optim
improv
express
construct
synthes
commerci
genscript
nj
usa
subclon
modifi
vaccin
express
vector
control
cytomegaloviru
immediateearli
promot
describ
previous
cell
plate
sixwel
plate
cellswel
transfect
hour
later
scmayv
empti
vector
control
plasmid
use
genejamm
transfect
reagent
agil
technolog
santa
clara
ca
usa
accord
manufactur
instruct
transfect
carri
optimem
medium
invitrogen
transfect
supernat
cell
lysat
collect
hour
post
transfect
antigen
express
confirm
western
blot
analysi
cell
wash
phosphatebuff
salin
pb
lyse
lysi
buffer
contain
mm
hcl
mm
nacl
nonidet
triton
sodium
dodecyl
sulfat
cocktail
proteas
inhibitor
roch
basel
switzerland
ice
minut
intermedi
vortex
minut
centrifug
rpm
supernat
collect
analyz
sodium
dodecyl
polyacrylamid
gel
electrophoresi
transfer
nitrocellulos
membran
immunoblot
antisera
dilut
scmayv
secondari
antibodi
coupl
horseradish
peroxidas
hrp
use
dilut
next
membran
strip
use
newblot
nitrocellulos
strip
buffer
licor
nebraska
usa
probe
rabbit
monoclon
antibodi
licor
usa
load
control
immunofluoresc
analysi
cell
seed
top
coverslip
cell
cultur
plate
wash
three
time
pb
cell
incub
hour
fluorescein
isothiocyan
fitc
conjug
goat
antihuman
igg
santa
cruz
biotechnolog
inc
usa
nucleu
stain
dapi
room
temperatur
minut
pb
wash
perform
incub
step
sampl
subsequ
mount
onto
glass
slide
use
fluoroshield
mount
medium
abcam
usa
view
confoc
microscop
carl
zeiss
result
imag
analyz
use
zen
softwar
fiveto
eightweek
old
femal
mice
jackson
laboratori
bar
harbor
usa
hous
vaccin
lightcycl
temperatureand
humiditycontrol
anim
facil
fourto
sixweek
old
mice
background
defici
receptor
ifnar
purchas
jackson
laboratori
mmrrc
repositoryth
jackson
laboratori
usa
establish
breed
coloni
approv
wistar
institut
anim
care
use
committe
iacuc
anim
bred
hous
barrier
anim
facil
wistar
institut
murin
studi
perform
accord
recommend
nation
institut
health
nih
wistar
institut
institut
anim
care
use
committe
dna
immun
fiveto
eightweekold
femal
mice
fourto
sixweek
old
ifnar
mice
mix
sex
deliv
dna
total
volum
steril
water
syring
anterior
tibiali
ta
muscl
site
immedi
electropor
cellectra
adapt
constant
current
enhanc
electropor
ep
deliveri
devic
inovio
pharmaceut
pa
usa
threeprong
minim
invas
devic
insert
mm
ta
muscl
prong
consist
solid
stainlesssteel
electrod
triangul
squarewav
puls
amp
deliv
msec
puls
twice
second
delay
insert
site
detail
ep
usag
previous
describ
detail
blood
collect
submandibular
method
preced
dna
inject
ep
procedur
mice
anesthet
isofluran
phoenix
clipper
mo
usa
procedur
group
receiv
one
two
three
immun
interv
mice
euthan
one
week
follow
last
immun
spleen
dissect
individu
crush
use
stomach
devic
seward
uk
splenocyt
strain
cell
strainer
thermofish
usa
treat
minut
ammoniumchloridepotassium
ack
lysi
buffer
qualiti
biolog
md
usa
lyse
red
blood
cell
splenocyt
resuspend
use
mous
elispot
plu
assay
mabtech
usa
accord
manufactur
instruct
briefli
splenocyt
scmayv
control
immun
mice
ad
well
incub
hour
co
either
presenc
media
alon
neg
control
media
cell
activ
cocktail
biolegend
usa
contain
premix
phorbol
pma
ionomycin
posit
control
media
peptid
pool
consist
linearli
pool
individu
peptid
overlap
amino
acid
span
length
mayv
envelop
protein
spot
form
addit
blue
tetrazolium
bcipnbt
color
develop
substrat
r
system
usa
spot
form
unit
sfu
quantifi
autom
elispot
reader
ctl
limit
usa
averag
number
sfu
media
alon
well
subtract
stimul
well
data
adjust
sfu
per
splenocyt
maxisorp
highbind
elisa
plate
thermofish
usa
coat
commerci
recombin
mayv
envelop
glycoprotein
alpha
diagnost
san
antonio
tx
usa
mayv
envelop
glycoprotein
alpha
diagnost
usa
concentr
coat
buffer
na
co
nahco
ph
overnight
plate
wash
time
pb
buffer
solut
contain
pbst
thermofish
usa
block
fb
pb
hour
serum
sampl
serial
dilut
start
dilut
factor
pb
contain
fb
ad
well
incub
hour
plate
wash
time
pbst
incub
hrplabel
goat
antimous
igg
sigmaaldrich
usa
hour
final
wash
fresh
tmb
substrat
sigmaaldrich
ad
per
well
incub
minut
reaction
stop
ad
h
optic
densiti
plate
measur
nm
biotek
elisa
plate
reader
biotek
usa
antibodi
endpoint
titer
defin
highest
dilut
serum
sampl
od
valu
mean
vaccin
mice
sampl
titer
given
endpoint
titer
assay
done
triplic
mous
igg
subtyp
pierc
rapid
antibodi
isotyp
kit
thermofish
usa
use
dilut
mous
sera
scmayv
immun
sera
background
singlecel
suspend
mous
splenocyt
ad
per
well
ubottom
plate
thermofish
cell
stimul
hour
co
either
presenc
media
alon
neg
control
media
cell
activ
cocktail
biolegend
contain
premix
pma
ionomycin
posit
control
media
mayv
envelop
peptid
span
length
entir
protein
sampl
contain
protein
transport
inhibitor
cocktail
ebiosci
san
diego
ca
usa
upon
complet
stimul
cell
wash
fac
buffer
pb
contain
sodium
azid
fb
cell
stain
surfac
protein
use
fluorochromeconjug
antibodi
per
manufactur
instruct
bd
bioscienc
san
diego
ca
usa
cell
wash
fac
buffer
fix
permeabil
use
bd
cytofixcytoperm
bd
bioscienc
per
manufactur
protocol
intracellular
cytokin
stain
use
fluorchromeconjug
antibodi
bd
bioscienc
follow
antibodi
use
surfac
stain
livedead
fixabl
violet
dead
cell
stain
kit
invitrogen
clone
bd
bioscienc
fitc
clone
ebiosci
clone
bd
bioscienc
clone
biolegend
intracellular
stain
follow
antibodi
use
apc
clone
biolegend
pe
clone
ebiosci
clone
biolegend
clone
ebiosci
lsrii
flow
cytomet
outfit
follow
laser
bandpass
filter
iv
red
data
collect
use
lsrii
flow
cytomet
bd
bioscienc
analyz
use
flowjo
softwar
tree
star
ashland
usa
spice
boolean
gate
perform
use
flowjo
softwar
examin
polyfunction
cell
vaccin
anim
trinidad
region
viru
laboratori
trvl
strain
mayv
obtain
atcc
atcc
passag
vero
cell
cultur
quantifi
previous
describ
one
week
second
immun
mice
either
scmayv
vaccin
vaccin
group
challeng
plaqueform
unit
pfu
mayv
dilut
steril
pb
deliv
gradual
intraperiton
p
inocul
mice
weigh
daili
evalu
clinic
sign
infect
follow
decreas
mobil
hunch
postur
footpad
swell
decreas
grip
strength
hindlimb
paralysi
hindlimb
moribund
wistar
institut
iacuc
approv
death
endpoint
mice
euthan
weight
loss
sustain
day
total
weight
loss
reach
bodi
weight
mice
exhibit
sign
clinic
symptom
list
concurr
day
mice
moribund
mice
exhibit
sign
symptom
mayv
infect
last
day
experi
whole
blood
collect
day
post
challeng
mayaro
viral
titer
quantif
describ
previous
footpad
swell
individu
mous
measur
calip
day
eight
day
post
challeng
number
surviv
mice
note
human
euthan
fourto
sixweek
old
ifnar
mice
immun
twice
twoweek
interv
one
week
second
immun
immun
sera
isol
whole
blood
combin
singl
pool
per
group
passiv
transfer
immun
sera
perform
intraperiton
ip
inject
per
mous
fourto
sixweek
old
naiv
ifnar
mice
mice
receiv
immun
sera
immun
group
pb
serv
neg
control
group
challeng
pfu
wildtyp
trvl
strain
mayv
monitor
daili
describ
fourto
sixweek
old
ifnar
mice
immun
twice
twoweek
interv
one
week
second
immun
mice
euthan
spleen
collect
process
singlecel
suspens
cell
viabil
examin
trypan
blue
dye
exclus
stain
use
countess
ii
autom
cell
counter
thermofish
adopt
transfer
perform
ip
inocul
fourto
sixweek
old
naiv
ifnar
mice
group
receiv
splenocyt
ip
immun
mice
pb
serv
neg
control
group
challeng
pfu
wildtyp
trvl
strain
mayv
monitor
daili
describ
prnt
assay
carri
detect
quantifi
presenc
neutral
antibodi
immun
mous
serum
sampl
previous
describ
heatinactiv
minut
immun
sera
dilut
serial
dilut
sampl
mix
equal
volum
pfu
wildtyp
trvl
strain
mayv
follow
incub
hour
virusantibodi
neutral
reaction
viru
serum
mixtur
use
inocul
monolay
vero
cell
plate
follow
incub
hour
rock
everi
minut
next
supernat
remov
well
layer
methyl
cellulos
ad
incub
co
day
cell
fix
stain
crystal
violet
thermofish
plaqu
number
record
describ
mayv
alon
without
serum
incub
serv
neg
control
wash
stain
cell
distil
water
airdri
plate
number
foci
per
well
count
use
stereomicroscop
percentag
infect
calcul
reduct
infect
number
plaqu
serum
sampl
number
plaqu
neg
control
purifi
human
monocyt
obtain
univers
pennsylvania
immunolog
core
philadelphia
usa
human
monocytederiv
macrophag
mdm
well
cultur
plate
macrophag
base
medium
dxf
promocel
gmbh
germani
supplement
ngml
granulocytemacrophag
colonystimul
factor
gmcsf
recombin
protein
r
system
usa
cultur
incub
without
disturb
co
day
mdm
wash
pb
prior
infect
cell
infect
pfu
trvl
strain
mayv
preincub
hour
either
immun
sera
dilut
pool
day
immun
sera
scmayv
vaccin
mice
media
contain
sera
virusscmayv
sera
mixtur
ad
wash
mdm
plate
kept
hour
rock
interv
minut
supernat
remov
follow
incub
macrophag
base
medium
dxf
promocel
gmbh
germani
ad
well
incub
co
hour
uninfect
infect
macrophag
stain
live
cell
label
kitgreen
fluorescencecytopaint
abcam
cambridg
usa
accord
manufactur
instruct
stain
macrophag
imag
microscop
evo
cell
imag
system
life
technolog
live
cell
ie
label
dye
green
assess
visual
inspect
imag
six
differ
review
assess
inhibit
infect
rel
baselin
monolay
vero
cell
plate
plate
inocul
supernat
mayvinfect
mdm
previous
preincub
mayv
either
scmayv
sera
hour
incub
viabil
vero
cell
examin
trypan
blue
dye
exclus
stain
use
countess
ii
autom
cell
counter
thermofish
assay
done
triplic
dot
repres
cell
viabil
singl
well
sem
experi
repeat
twice
result
repres
least
two
independ
experi
similar
result
graph
standard
curv
pie
chart
made
use
graphpad
prism
version
softwar
ic
valu
calcul
use
nonlinear
regress
reciproc
serum
dilut
compar
control
surviv
data
mous
experi
graph
use
kaplanmei
surviv
curv
twotail
p
valu
calcul
logrank
mantelcox
test
nonparametr
data
use
graphpad
prism
version
softwar
employ
bioinformat
synthet
dna
technolog
creat
novel
dna
vaccin
encod
fulllength
mayv
envelop
gene
sequenc
compris
glycoprotein
domain
well
polypeptid
synthet
dna
insert
creat
align
fulllength
envelop
genom
sequenc
multipl
mayv
strain
deposit
genbankncbi
nation
center
biotechnolog
inform
databas
determin
common
conserv
amino
acid
posit
consensu
antigen
sequenc
account
genet
variabl
occur
time
sequenc
thu
map
phylogenet
midpoint
fig
studi
show
synthet
consensu
sequenc
focu
immun
respons
conserv
site
well
broaden
cell
immun
improv
transcript
translat
vaccin
insert
modif
insert
sequenc
made
prior
clone
modifi
vaccin
express
vector
name
addit
immunoglobulin
e
ige
leader
sequenc
nterminu
fig
along
codon
rna
optim
sequenc
refer
model
scmayv
antigen
made
use
discoveri
studio
softwar
indic
predict
structur
match
wildtyp
mayv
envelop
fusion
loop
end
domain
tuck
fold
domain
fig
thu
preserv
import
envelop
function
site
express
scmayv
antigen
confirm
vitro
western
analys
cell
lysat
transfect
scmayv
vaccin
fig
immunogen
scmayv
vaccin
evalu
mice
initi
group
mice
immun
three
time
two
week
apart
either
scmayv
empti
vector
plasmid
use
epenhanc
intramuscular
im
deliveri
immun
mice
bled
day
one
week
inject
obtain
sera
assay
presenc
antibodi
mayv
envelop
use
elisa
commerci
avail
mayv
glycoprotein
result
show
mice
develop
antimayv
antibodi
singl
immun
fig
antimayv
igg
respons
boost
second
third
immun
fig
presenc
respons
murin
sera
post
third
immun
day
confirm
via
western
blot
analysi
use
commerci
avail
glycoprotein
load
antigen
cell
lysat
neg
control
fig
multipl
immun
also
enhanc
affin
vaccineinduc
antimayv
respons
glycoprotein
evidenc
increas
endpoint
titer
second
third
immun
fig
compar
increas
total
subtyp
third
immun
fig
fig
mg
neuron
cell
fig
infect
wildtyp
mayv
could
identifi
indirect
immunofluoresc
assay
use
pool
day
sera
scmayv
immun
mice
use
pool
day
sera
studi
relat
alphavirus
includ
chikv
establish
antivir
antibodi
primari
correl
protect
next
evalu
whether
antibodi
respons
elicit
scmayv
vaccin
mice
could
neutral
mayv
infect
vitro
plaqu
reduct
neutral
test
prnt
perform
pool
day
sera
scmayv
western
blot
analysi
scmayv
immun
murin
sera
pool
day
sera
aforement
experi
use
primari
antibodi
probe
glycoprotein
cell
lysat
neg
control
igg
endpoint
titer
scmayv
vaccin
mous
sera
immun
antibodi
endpoint
titer
defin
highest
dilut
serum
sampl
od
valu
mean
vaccin
mice
sampl
titer
given
endpoint
titer
e
igg
endpoint
titer
scmayv
vaccin
mous
immun
day
sera
use
calcul
endpoint
titer
perform
f
igg
subclass
isotyp
mous
sera
scmayv
mous
sera
one
week
post
third
immun
day
group
shown
n
g
indirect
immunofluoresc
assay
mayvinfect
vero
cell
incub
pool
day
sera
scmayv
immun
mice
follow
fitctag
antimous
igg
secondari
antibodi
green
dapi
blue
identifi
nuclei
h
indirect
immunofluoresc
assay
mayvinfect
neuron
cell
incub
pool
day
sera
scmayv
dna
immun
mice
follow
fitctag
antimous
igg
secondari
antibodi
green
dapi
blue
identifi
nuclei
plaqu
reduct
neutral
assay
prnt
heatinactiv
pool
day
sera
uninfect
naiv
scmayv
immun
mice
serial
twofold
dilut
sera
incub
pfu
mayv
hour
ad
well
confluent
vero
cell
plaqu
format
well
score
day
post
infect
reduct
plaqu
format
calcul
comparison
plaqu
form
well
receiv
viru
prnt
valu
calcul
nonlinear
regress
analysi
use
prism
softwar
immun
immun
uninfect
control
mice
antibodi
scmayv
vaccin
mice
neutral
mayv
infect
cell
high
neutral
titer
ic
immun
sera
uninfect
control
sera
abl
neutral
viru
highest
serum
dilut
fig
result
indic
scmayv
induc
robust
mayvspecif
humor
respons
mice
capabl
block
mayv
infect
vitro
multipl
alphavirus
known
infect
macrophag
cell
believ
play
role
alphavirusinduc
arthriti
assess
potenti
scmayv
immun
sera
protect
macrophag
infect
vitro
infect
assay
perform
addit
wildtyp
mayv
trvl
human
monocytederiv
macrophag
mdm
progress
decreas
cell
viabil
hour
post
infect
fig
importantli
preincub
mayv
trvl
pool
sera
scmayv
immun
mice
significantli
increas
viabil
mdm
wherea
mdm
incub
mayv
sera
demonstr
high
level
cell
death
observ
visual
field
novel
dna
vaccin
mayaro
viru
use
phasecontrast
fluoresc
microscop
fig
percent
live
cell
label
label
dye
green
seen
fluoresc
green
cell
evalu
six
independ
review
fig
result
led
conclus
mayv
like
induc
cell
death
sera
scmayv
immun
mice
significantli
increas
mdm
viabil
presenc
mayv
investig
observ
cocultur
hour
vero
cell
plate
supernat
infect
mdm
preincub
scmayv
sera
sera
vero
cell
maintain
presenc
supernat
mdm
incub
mayvscmayv
immun
sera
cell
viabil
compar
cell
viabil
vero
cell
cultur
presenc
mdm
supernat
incub
sera
fig
taken
togeth
result
suggest
scmayv
immun
sera
capabl
inhibit
viral
replic
mdm
next
evalu
antimayv
cellular
immun
splenocyt
collect
scmayv
immun
mice
one
week
third
immun
day
control
scmayv
immun
mice
euthan
bulk
splenocyt
obtain
elispot
assay
briefli
harvest
splenocyt
mice
ex
vivo
stimul
variou
peptid
pool
encompass
fulllength
mayv
envelop
protein
ie
glycoprotein
ident
peptid
pool
shown
tabl
antigenspecif
product
interferon
gamma
cell
report
spot
form
unit
sfu
per
million
cell
mice
immun
scmayv
exhibit
robust
cellular
respons
multipl
peptid
pool
throughout
mayv
envelop
glycoprotein
domain
fig
similar
robust
cellular
respons
multipl
mayv
peptid
pool
also
observ
separ
cohort
mice
receiv
singl
immun
scmayv
vaccin
fig
better
defin
domin
epitop
scmayv
elicit
cellular
respons
mous
model
elispot
map
analysi
perform
bulk
splenocyt
mice
receiv
three
immun
scmayv
thirtyf
matrix
peptid
pool
encompass
entir
mayv
envelop
protein
compris
individu
peptid
overlap
amino
acid
creat
tabl
ex
vivo
stimul
splenocyt
elispot
assay
previous
describ
sever
matrix
pool
differ
region
mayv
envelop
glycoprotein
domain
identifi
cell
matrix
pool
elicit
highest
respons
region
well
region
fig
subsequ
map
analysi
identifi
domin
epitop
within
mayv
glycoprotein
grsvihfstasaap
fig
within
glycoprotein
lakcppgevisvsfv
fig
amino
acid
sequenc
domin
epitop
determin
elispot
map
analysi
confirm
use
immun
epitop
databas
analysi
resourc
tool
http
toolsiedborg
substanti
effect
antigen
process
scmayv
vaccin
strain
mice
character
cellular
respons
induc
scmayv
vaccin
splenocyt
collect
mice
receiv
three
immun
scmayv
control
evalu
polychromat
flow
cytometri
panel
fluorophoretag
antibodi
creat
use
character
helper
cytotox
cell
product
activatedst
cytokin
tumor
necrosi
interleukin
post
ex
vivo
stimul
bulk
splenocyt
peptid
compris
mayv
fulllength
envelop
cell
isol
scmayv
vaccin
mice
abl
produc
intracellular
cytokin
upon
stimul
mayv
peptid
fig
scmayv
vaccin
also
induc
polyfunct
respons
cell
subset
ie
product
multipl
activatedst
cytokin
singl
cell
indic
presenc
tripleposit
cell
subset
red
fig
combin
elispot
result
scmayv
dna
vaccin
induc
cellular
immun
mayv
polyfunction
antigenspecif
cell
next
evalu
whether
vaccineinduc
mayvspecif
respons
could
protect
mayv
infect
diseas
anim
challeng
model
previou
studi
show
older
immunocompet
mous
model
exhibit
arthritogen
sign
diseas
upon
alphaviru
challeng
therefor
chose
use
interferon
receptor
knockout
mous
ifnar
model
defect
innat
immun
respons
pathogen
establish
dose
pfu
mayv
administ
ip
produc
measur
clinic
sign
diseas
includ
weight
loss
foot
swell
criteria
euthanasia
first
cellular
humor
immunogen
scmayv
vaccin
ifnar
mice
evalu
previous
describ
mice
confirm
mount
similar
adapt
immun
respons
elispot
respons
fig
antigenspecif
igg
endpoint
titer
fig
compar
observ
mice
challeng
studi
cohort
fourto
sixweek
old
ifnar
mice
similarli
immun
twice
two
week
apart
either
scmayv
vaccin
empti
vector
plasmid
control
anim
challeng
day
one
week
second
immun
pfu
wildtyp
mayv
check
daili
day
clinic
sign
infect
mice
receiv
empti
vector
plasmid
exhibit
signific
progress
weight
loss
fig
contrast
mice
vaccin
scmayv
initi
minor
weight
loss
first
day
challeng
exhibit
slight
weight
gain
day
post
challeng
fig
percent
bodi
weight
chang
day
compar
scmayv
group
pvalu
importantli
vaccin
mice
surviv
challeng
control
mice
met
euthanasia
criteria
day
post
challeng
fig
group
also
signific
footpad
swell
day
post
challeng
fig
quantif
mayv
sera
collect
day
post
challeng
show
scmayv
vaccin
mice
signific
reduct
circul
viru
compar
inject
mice
fig
combin
data
demonstr
immun
respons
induc
scmayv
vaccin
provid
protect
morbid
viral
load
follow
mayv
challeng
murin
challeng
model
next
evalu
rel
contribut
scmayv
vaccin
induc
humor
cellular
respons
vivo
passiv
adapt
transfer
mayv
challeng
model
investig
cohort
fourto
sixweekold
ifnar
mice
immun
twice
twoweek
interv
scmayv
one
week
follow
final
immun
mice
euthan
blood
bulk
splenocyt
collect
anim
sera
splenocyt
group
pool
cohort
naiv
fourto
sixweek
old
ifnar
mice
inject
either
pb
pool
immun
sera
pool
splenocyt
contain
cell
subsequ
challeng
pfu
mayv
ip
one
hour
post
passiv
adapt
transfer
challeng
mice
monitor
day
clinic
sign
diseas
mice
receiv
pb
prior
challeng
progress
lost
weight
eventu
euthan
due
sever
diseas
expect
day
adopt
transfer
cell
immun
mice
provid
protect
weight
loss
fig
partial
protect
diseas
fig
significantli
mice
receiv
scmayv
immun
sera
exhibit
weight
loss
fig
surviv
challeng
fig
combin
data
establish
scmayv
induc
humor
respons
main
driver
protect
efficaci
murin
mayv
challeng
model
mayaro
viru
emerg
infecti
diseas
agent
endem
tropic
region
south
america
recent
evid
suggest
rang
may
expand
central
america
island
nation
caribbean
sea
viru
caus
acut
febril
ill
symptom
includ
rash
headach
nausea
diarrhea
turn
debilit
longterm
arthralgia
patient
acut
infect
clear
current
approv
vaccin
therapeut
combat
mayv
diseas
spread
report
gener
immunogen
scmayv
synthet
enhanc
dna
vaccin
encod
novel
consensusdesign
sequenc
mayvenvelop
glycoprotein
immun
mice
scmayv
use
enhanc
ep
deliveri
induc
robust
mayvspecif
humor
cellular
respons
importantli
respons
neutral
mayv
infect
vitro
fulli
protect
suscept
mice
morbid
mortal
follow
mayv
challeng
result
show
scmayv
highli
immunogen
vaccin
candid
warrant
test
addit
system
anim
model
develop
countermeasur
mayv
infect
diseas
precis
correl
protect
mayv
defin
recent
oneyear
longitudin
studi
confirm
mayvinfect
individu
peru
found
infect
elicit
robust
antivir
immun
respons
includ
strong
neutral
antibodi
respons
secret
proinflammatori
immun
cytokin
includ
vegf
also
report
strong
neutral
antibodi
respons
suffici
prevent
longterm
neg
outcom
mayv
infect
howev
humor
respons
develop
post
infect
studi
relat
alphavirus
includ
chikv
strongli
suggest
potent
neutral
antibodi
respons
primarili
mediat
protect
infect
non
novel
dna
vaccin
mayaro
viru
neutral
antibodi
may
contribut
protect
well
altern
effector
function
post
infect
like
import
role
cellular
immun
may
complement
humor
respons
studi
need
address
import
issu
scmayv
dna
vaccin
elicit
humor
cellular
respons
mayv
consequ
import
tool
provid
comprehens
protect
mayv
infect
diseas
antibodi
mayv
gener
initi
prime
immun
scmayv
respons
increas
one
two
boost
term
bind
capac
affin
immun
sera
vaccin
mice
abl
detect
fulllength
mayv
envelop
scmayv
transfect
cell
well
mayv
infect
cell
scmayv
vaccin
mice
abl
induc
neutral
antibodi
block
viral
entri
inhibit
cell
death
induc
mayv
infect
human
mdm
passiv
transfer
immun
sera
scmayv
vaccin
mice
suscept
naiv
ifnar
mice
prior
mayv
challeng
complet
protect
anim
ill
confirm
import
strong
humor
respons
confer
protect
alphaviru
infect
although
antimayv
cell
respons
appear
less
import
immedi
protect
mayv
infect
may
still
essenti
prevent
chronic
diseas
elimin
virusinfect
cell
cellular
compon
induc
scmayv
dna
vaccin
target
multipl
epitop
along
fulllength
mayv
envelop
glycoprotein
strongest
cellular
respons
direct
epitop
domain
envelop
wherea
respons
epitop
glycoprotein
less
robust
epitop
map
studi
use
elispot
assay
identifi
two
immunodomin
epitop
lakcppgevisvsfv
domain
grsvihfstasaap
within
domain
provid
novel
dna
vaccin
mayaro
viru
import
use
reagent
studi
cell
immun
respons
haplotyp
interestingli
adapt
transfer
splenocyt
scmayv
immun
mice
suscept
naiv
ifnar
mice
prior
mayv
challeng
provid
partial
protect
weight
loss
clinic
symptom
mayv
diseas
suggest
mayvspecif
cellular
respons
contribut
protect
adopt
transfer
experi
mayvspecif
cell
purifi
enrich
bulk
splenocyt
prior
transfer
thu
possibl
partial
protect
observ
could
enhanc
larger
dose
antigenspecif
cell
immunogen
scmayv
dna
vaccin
mirror
observ
previou
dna
vaccin
candid
target
chikungunya
viru
chikv
encod
synthet
consensu
sequenc
fulllength
chikungunya
envelop
protein
chikv
vaccin
similarli
abl
gener
humor
cellular
respons
direct
toward
chikv
envelop
protein
respons
could
protect
mice
morbid
mortal
follow
chikv
challeng
synthet
dna
vaccin
practic
advantag
develop
includ
eas
manufactur
stabil
warmer
temperatur
like
reduc
requir
cold
chain
nonliv
nonrepl
integr
thu
provid
conceptu
safeti
advantag
well
sinc
dna
vaccin
vector
induc
antivector
serolog
administ
multipl
time
loss
potenc
without
interf
vaccin
protocol
logist
safeti
advantag
warrant
studi
vaccin
approach
especi
pertain
diseas
preval
resourcepoor
tropic
set
mayv
preval
best
knowledg
scmayv
third
vaccin
candid
mayv
develop
first
vaccin
inactiv
mayaro
viru
second
candid
report
liveattenu
mayv
vaccin
prior
vaccin
shown
induc
antimayv
humor
respons
could
protect
mice
mayv
challeng
neither
studi
report
induct
cellular
respons
mayv
synthet
scmayv
dna
vaccin
describ
gener
mayvspecif
humor
cellular
respons
without
viral
replic
like
import
immunechalleng
young
pregnant
elderli
popul
potenti
travel
resid
endem
area
need
vaccineinduc
immun
protect
addit
studi
vaccin
approach
use
dna
platform
provid
insight
rel
merit
method
field
